Primary aldosteronism - Treatment options

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Diagnosis of primary aldosteronism results in either the surgical cure of hypertension or targeted pharmacotherapy. The two major subtypes of primary aldosteronism are unilateral aldosterone-producing adenoma (APA) and bilateral idiopathic hyperaldosteronism (IHA). Patients with APA usually are treated with unilateral adrenalectomy and patients with IHA are treated medically. The majority of patients with primary aldosteronism have the IHA subtype and require pharmacotherapy. Spironolactone has been the drug of choice to treat primary aldosteronism. However, it is not selective for the aldosterone receptor, and side effects include gynecomastia, erectile dysfunction and menstrual irregularity. Eplerenone is a new competitive and selective aldosterone receptor antagonist recently approved by the United States Food and Drug Administration for the treatment of hypertension. It lacks the side effects associated with spironolactone and will be the superior drug if it is shown to be as effective as spironolactone for the treatment of mineralocorticoid-dependent hypertension.

Original languageEnglish (US)
JournalGrowth Hormone and IGF Research
Volume13
Issue numberSUPPL. A
DOIs
StatePublished - Aug 2003

Fingerprint

Hyperaldosteronism
Spironolactone
Hypertension
Aldosterone
Adenoma
Therapeutics
Mineralocorticoid Receptor Antagonists
Gynecomastia
Drug Therapy
Mineralocorticoid Receptors
Mineralocorticoids
Adrenalectomy
Erectile Dysfunction
United States Food and Drug Administration
Pharmaceutical Preparations

Keywords

  • Aldosterone
  • Eplerenone
  • Primary aldosteronism
  • Spironolactone

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Primary aldosteronism - Treatment options. / Young, William Francis.

In: Growth Hormone and IGF Research, Vol. 13, No. SUPPL. A, 08.2003.

Research output: Contribution to journalArticle

@article{8b67f7f75fb14f25bbaef699eb3f2328,
title = "Primary aldosteronism - Treatment options",
abstract = "Diagnosis of primary aldosteronism results in either the surgical cure of hypertension or targeted pharmacotherapy. The two major subtypes of primary aldosteronism are unilateral aldosterone-producing adenoma (APA) and bilateral idiopathic hyperaldosteronism (IHA). Patients with APA usually are treated with unilateral adrenalectomy and patients with IHA are treated medically. The majority of patients with primary aldosteronism have the IHA subtype and require pharmacotherapy. Spironolactone has been the drug of choice to treat primary aldosteronism. However, it is not selective for the aldosterone receptor, and side effects include gynecomastia, erectile dysfunction and menstrual irregularity. Eplerenone is a new competitive and selective aldosterone receptor antagonist recently approved by the United States Food and Drug Administration for the treatment of hypertension. It lacks the side effects associated with spironolactone and will be the superior drug if it is shown to be as effective as spironolactone for the treatment of mineralocorticoid-dependent hypertension.",
keywords = "Aldosterone, Eplerenone, Primary aldosteronism, Spironolactone",
author = "Young, {William Francis}",
year = "2003",
month = "8",
doi = "10.1016/S1096-6374(03)00064-9",
language = "English (US)",
volume = "13",
journal = "Endocrinology and Metabolism, Supplement",
issn = "1096-6374",
publisher = "Churchill Livingstone",
number = "SUPPL. A",

}

TY - JOUR

T1 - Primary aldosteronism - Treatment options

AU - Young, William Francis

PY - 2003/8

Y1 - 2003/8

N2 - Diagnosis of primary aldosteronism results in either the surgical cure of hypertension or targeted pharmacotherapy. The two major subtypes of primary aldosteronism are unilateral aldosterone-producing adenoma (APA) and bilateral idiopathic hyperaldosteronism (IHA). Patients with APA usually are treated with unilateral adrenalectomy and patients with IHA are treated medically. The majority of patients with primary aldosteronism have the IHA subtype and require pharmacotherapy. Spironolactone has been the drug of choice to treat primary aldosteronism. However, it is not selective for the aldosterone receptor, and side effects include gynecomastia, erectile dysfunction and menstrual irregularity. Eplerenone is a new competitive and selective aldosterone receptor antagonist recently approved by the United States Food and Drug Administration for the treatment of hypertension. It lacks the side effects associated with spironolactone and will be the superior drug if it is shown to be as effective as spironolactone for the treatment of mineralocorticoid-dependent hypertension.

AB - Diagnosis of primary aldosteronism results in either the surgical cure of hypertension or targeted pharmacotherapy. The two major subtypes of primary aldosteronism are unilateral aldosterone-producing adenoma (APA) and bilateral idiopathic hyperaldosteronism (IHA). Patients with APA usually are treated with unilateral adrenalectomy and patients with IHA are treated medically. The majority of patients with primary aldosteronism have the IHA subtype and require pharmacotherapy. Spironolactone has been the drug of choice to treat primary aldosteronism. However, it is not selective for the aldosterone receptor, and side effects include gynecomastia, erectile dysfunction and menstrual irregularity. Eplerenone is a new competitive and selective aldosterone receptor antagonist recently approved by the United States Food and Drug Administration for the treatment of hypertension. It lacks the side effects associated with spironolactone and will be the superior drug if it is shown to be as effective as spironolactone for the treatment of mineralocorticoid-dependent hypertension.

KW - Aldosterone

KW - Eplerenone

KW - Primary aldosteronism

KW - Spironolactone

UR - http://www.scopus.com/inward/record.url?scp=0141520270&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141520270&partnerID=8YFLogxK

U2 - 10.1016/S1096-6374(03)00064-9

DO - 10.1016/S1096-6374(03)00064-9

M3 - Article

C2 - 12914736

AN - SCOPUS:0141520270

VL - 13

JO - Endocrinology and Metabolism, Supplement

JF - Endocrinology and Metabolism, Supplement

SN - 1096-6374

IS - SUPPL. A

ER -